deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00897130

5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs) (MDSAZA0706)

Clinical and Biological Effects of 5-Azacitidine Five Days/Monthly Schedule in Symptomatic Low-risk Myelodysplastic Syndromes (MDSs)

Sponsor: Cremona

Conditions Myelodysplastic Syndrome
Interventions Azacytidine
Updated 5 times since 2017 Last updated: Dec 2, 2014 Started: Aug 31, 2008 Primary completion: Dec 31, 2009 Completion: Dec 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Myelodysplastic Syndrome, this trial is completed. The trial is conducted by Cremona and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cremona
  • Mantova
  • University of Bologna
  • University of Genova
  • University of Siena
  • University of Udine
  • Università degli Studi di Brescia
Data source: Università degli Studi di Brescia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations